Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
International Journal of Oncology|October 14, 2015
Clinical significance of expanded Foxp3⁺ Helios⁻ regulatory T cells in patients with non-small cell lung cancerSatoshi Muto, Yuki Owada, Takuya Inoue, et al.
Journal of Thoracic Disease|August 18, 2020
A phase 2 study of adjuvant carboplatin plus S-1 followed by maintenance S-1 therapy for patients with completely resected stage II/IIIA non-small cell lung cancer-Japanese Northern East Area Thoracic Surgery Study Group JNETS1302 studyTakeo Hasegawa, Hiroyuki Suzuki, Jiro Abe, et al.
Anticancer Research|May 29, 2017
Serum Nitric Oxide as a Predictive Biomarker for Bevacizumab in Non-small Cell Lung Cancer PatientsSatoshi Muto, Hironori Takagi, Yuki Owada, et al.
Fukushima Journal of Medical Science|February 21, 2018
Comparison of surgical outcomes after pneumonectomy and pulmonary function-preserving surgery for non-small cell lung cancerMitsunori Higuchi, Hironori Takagi, Yuki Ozaki, et al.
Scientific Reports|June 16, 2021
CLDN15 is a novel diagnostic marker for malignant pleural mesotheliomaMasayuki Watanabe, Tomohito Higashi, Kana Ozeki, et al.
Journal of Translational Medicine|April 13, 2013
Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancerHiroyuki Suzuki, Mitsuro Fukuhara, Takumi Yamaura, et al.
Oncology Letters|May 12, 2020
Genetic alterations in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinomaTakumi Yamaura, Satoshi Muto, Hayato Mine, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|September 16, 2017
[Exploring the Possibility of New Biomarkers of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer (NSCLC)]Yuki Owada, Takuya Inoue, Yuzuru Watanabe, et al.
Human Vaccines & Immunotherapeutics|November 8, 2013
Recent advances in immunotherapy for non-small-cell lung cancerHiroyuki Suzuki, Yuki Owada, Yuzuru Watanabe, et al.
Journal of Skin Cancer|March 28, 2013
Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite NanoparticlesKowichi Jimbow, Yasue Ishii-Osai, Shosuke Ito, et al.
Pageof 7